cell neoplasm
Recently Published Documents


TOTAL DOCUMENTS

1051
(FIVE YEARS 103)

H-INDEX

43
(FIVE YEARS 0)

Author(s):  
Cameron J. Overfield ◽  
Mark A. Edgar ◽  
Daniel E. Wessell ◽  
Benjamin K. Wilke ◽  
Hillary W. Garner


eJHaem ◽  
2022 ◽  
Author(s):  
Shaoying Li ◽  
Jie Xu ◽  
C. Cameron Yin ◽  
Sergej Konoplev


eJHaem ◽  
2022 ◽  
Author(s):  
Grégoire Stalder ◽  
Dina Milowich ◽  
Sabine Blum ◽  
Jacqueline Schoumans ◽  
Bettina Bisig ◽  
...  


2022 ◽  
Vol 11 ◽  
Author(s):  
Federica Recine ◽  
Alessandro De Vita ◽  
Valentina Fausti ◽  
Federica Pieri ◽  
Alberto Bongiovanni ◽  
...  

BackgroundNTRK (neurotrophic tyrosine receptor kinase)-rearranged spindle cell neoplasms are a new group of tumors included in the new 5th edition of the World Health Organization (WHO) classification of soft Tissue and Bone Sarcomas. These tumors are characterized by NTRK gene fusions and show a wide spectrum of histologies and clinical behavior. Several targeted therapies have recently been approved for tumors harboring NTRK fusions, including STS.Case PresentationA 26-year-old male with advanced, pretreated NTRK rearranged spindle cell neoplasm and liver, lung and bone metastases was treated with larotrectinib on a continuous 28-day schedule, at a dose of 100 mg twice daily. An 18FDG-PET/CT scan performed after 7 days of treatment showed tumor shrinkage in both visceral and bone lesions. There was no drug-related toxicity. Subsequent evaluations confirmed continued tumor regression in disease sites. The patient is well and continues treatment.ConclusionThe clinical and radiological response of our patient with an uncommon TPM4 (exon 7)-NTRK1 (exon 12) gene fusion tumor treated with a first-generation TRK inhibitor could contribute to a better understanding of the biology of this new STS entity and help to improve patient management.



2022 ◽  
Vol 13 ◽  
pp. 7
Author(s):  
Luis David Molina Andaluz ◽  
Josué Alejandro Cervantes Gonzalez ◽  
Zita Elizabeth Salazar Ramírez ◽  
Nelly Ramírez ◽  
Luis Guillermo Castellanos ◽  
...  

Background: Solitary bone plasmacytoma is a plasmatic cell dyscrasia; its presentation in the posterior fossa is very rare. Case Description: We present two cases, a 59-year-old male and a 50-year-old female, both with heterogeneous clinical presentation. One had symptoms compatible with endocranial hypertension, and the other presented with a hemispheric cerebellar syndrome and ipsilateral trigeminal neuralgia. They were both related to an intraosseous tumor of the occipital region near the torcula with large extension to the posterior fossa. The diagnosis of a plasma cell neoplasm arising from the diploe of the squamous portion of the occipital bone was confirmed with immunohistochemistry. Conclusion: The treatment for a cranial tumor that is suspected to be a solitary bone plasmacytoma requires a multidisciplinary team to diagnose, plan a total resection, and after surgery continue with the follow-up of the patient. Solitary bone plasmacytoma should be considered as a differential diagnosis for a tumor that produces cancellous bone widening without sclerotic borders.



Author(s):  
Akihiro Takamiya ◽  
Yuki Ishibashi ◽  
Naohiro Makise ◽  
Makoto Hirata ◽  
Tetsuo Ushiku ◽  
...  


2022 ◽  
Author(s):  
thomas Hueso ◽  
Anne-Sophie Godron ◽  
Emily Lanoy ◽  
Jerome Pakanowski ◽  
Laura I Levi ◽  
...  

Patients with hematological malignancies and COVID-19 display a high mortality rate. In such patients, immunosuppression due to underlying disease and previous specific treatment impair humoral response, limiting viral clearance. Thus, COVID-19 convalescent plasma (CCP) therapy appears as a promising approach through the transfer of neutralizing antibodies specific to SARS-CoV-2. We report the effect of CCP in a cohort of 112 patients with hematological malignancies and COVID19 and a propensity score analysis on subgroups of patients with B-cell lymphoid disease treated (n=81) or not (n=120) with CCP between 1 May 2020 and 1 April 2021. The overall survival of the whole cohort was 65% [56-74.9] and 77.5% [68.5-87.7] for patients with B-cell neoplasm. Prior anti-CD20 monoclonal antibodies therapy was associated with better overall survival whereas age, high blood pressure, and COVID-19 severity were associated with a poor outcome. After an inverse probability of treatment weighting approach, we observed in anti-CD20 exposed patients with B-cell lymphoid disease a decreased mortality of 63% (95% CI=31%-80%) in the CCP-treated group compared to the CCP-untreated subgroup, confirmed in the other sensitivity analyses. Convalescent plasma may be beneficial in COVID-19 patients with B-cell neoplasm who are unable to mount a humoral immune response.



2021 ◽  
Author(s):  
Yu-Chien Kao ◽  
Pei-Hang Lee ◽  
Cheng-Lin Wu ◽  
Shih-Chen Yu ◽  
Hsuan-Ying Huang


Author(s):  
Jun Guan ◽  
Ying Zhou ◽  
xia Mao ◽  
Liang Zou ◽  
Hui Cheng

We enrolled a patient diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) . We have found that TET2, KRAS and BRAF may be involved in the development of the disease, and the combination therapy of Decitabine (DAC) and Arsenic acid (ASO) may be effective for BPDCN harboring the TET2 mutations.



Sign in / Sign up

Export Citation Format

Share Document